Robert J. More, a director of Vir Biotechnology, Inc. (NASDAQ:VIR), filed a Form 4 on August 12, 2026, reporting a transaction dated August 11, 2026, in which 8,000 shares of common stock were transferred to Alta Partners NextGen Fund I, L.P. at no consideration in connection with the vesting of restricted stock unit awards.

Key Highlights

  • Reporting person: Robert J. More, identified as a Director of Vir Biotechnology, Inc.
  • Transaction date: August 11, 2026, with the form filed August 12, 2026.
  • Transfer: 8,000 shares of common stock disposed of at $0 and 8,000 shares acquired at $0, via transaction code J.
  • Direct holdings after transaction: 40,656 shares held directly by the reporting person.
  • Indirect holdings after transaction: 517,917 shares held indirectly through Alta Partners NextGen Fund I, L.P. (APNG 1).
  • Context: The transfer was made in connection with the vesting of restricted stock unit (RSU) awards, according to the filing.

RSU-Related Transfer Between Robert J. More and Alta Partners NextGen Fund I

According to the filing, Robert J. More transferred 8,000 shares of Vir Biotechnology common stock that he held for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) directly to APNG 1 for no consideration. The transaction, coded "J," was reported in both Table I rows: a disposition of 8,000 shares from his direct holdings and a corresponding acquisition of 8,000 shares in the indirect account associated with APNG 1, both at a price of $0.

The filing states that the shares transferred were connected to the vesting of RSU awards. Following the transaction, More directly beneficially owns 40,656 shares of common stock. The 517,917 shares reported as indirectly owned are held by APNG 1. The filing explains that More is a managing director of Alta Partners NextGen Fund I Management, LLC, which serves as the general partner of APNG 1, and that as a result he "may be deemed to beneficially own the shares held by APNG 1."

The filing includes a disclaimer: More "disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein," and states that "this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise." The form was signed by Lorin Wagner as Attorney-In-Fact on August 12, 2026.

What Was Disclosed

Director Robert J. More reported the transfer of 8,000 Vir Biotechnology common shares to Alta Partners NextGen Fund I, L.P. at no cost, related to RSU vesting, leaving him with 40,656 shares directly and 517,917 shares indirectly following the transaction.